ARBs Safe for Long-Term Use: No Increased Cancer Risk
Angiotensin II receptor blockers (ARBs) are a common treatment for high blood pressure, heart failure, and kidney disease. Recent studies and the FDA confirm no increased cancer risk for those taking ARBs.
First approved in the US in 1995, losartan was the initial ARB. Today, common ARBs include azilsartan, candesartan, eprosartan mesylate, olmesartan, irbesartan, losartan potassium, telmisartan, and valsartan. These medications work by blocking angiotensin II receptors, reducing blood vessel tightening and lowering blood pressure.
Prescribed for various conditions, ARBs can benefit those who have had a heart attack, kidney disease, coronary artery disease, or abdominal obesity with high blood pressure. They can also be an alternative for those experiencing side effects from ACE inhibitors. Studies show ARBs can decrease the risk of heart attack, stroke, and cognitive decline in kidney disease patients.
While generally well-tolerated, ARBs can cause side effects such as headache, dizziness, fatigue, and respiratory symptoms. It's crucial to discuss any concerns with a healthcare provider, as individual responses may vary.
ARBs are a proven treatment for high blood pressure and related conditions, with no increased cancer risk. They can reduce the risk of cardiovascular events and may protect against cognitive decline. However, they should not be used during pregnancy due to potential adverse health outcomes. Always consult a doctor for personalized advice.
Read also:
- FDA's Generic Mifepristone Approval Sparks Pro-Life Concerns Over Safety and States' Rights
- Understanding Child Development: Causes and Signs of Delays
- Pope Francis' New Book 'Let Us Dream' Offers Unity and Hope for Post-Covid World
- Stephanie Estremera Gonzalez: From Medical Assistant to Residential Manager at The Point/Arc
